The total trade value of SCO Member States has increased nearly 100 times over the past 20 years

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

Unpacking China | Key Chinese Firms to Watch This Week （05/07/2026-11/07/2026）

Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.

Huawei Schedules Global Launch of Pura 90 in Malaysia, Signaling Potential Return of 5G Smartphones to Overseas Markets

Huawei Technologies (华为) has announced that it will hold the international launch event for its new Pura 90 series in Kuala Lumpur, Malaysia, on July 14, marking one of the company’s most closely watched overseas smartphone releases in recent years.

JD.com (京东) Wins Conditional Approval for €22 Billion Ceconomy Takeover, Gaining Control of Europe’s Largest Electronics Retail Network

Germany’s Federal Ministry for Economic Affairs has conditionally approved JD.com (京东)’s proposed €22 billion acquisition of Ceconomy, the European consumer electronics retailer that owns the MediaMarkt and Saturn chains. The decision marks a major milestone in the transaction and would make JD.com the controlling shareholder of one of Europe’s largest consumer electronics retail networks once the remaining regulatory approvals are secured.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.